share_log

Universe Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Universe Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

大自然藥業 | 6-K:外國發行人報告
美股SEC公告 ·  2024/07/19 04:06

Moomoo AI 已提取核心訊息

Universe Pharmaceuticals has successfully completed its self-underwritten public offering on July 15, 2024, raising $25 million before expenses. The offering consisted of 20 million ordinary shares priced at $1.25 per share, with a par value of $0.01875 per share.The company, headquartered in Jiangxi, China, executed this capital raising initiative through a self-managed offering process, demonstrating direct market engagement. The funds were raised before deducting offering-related expenses, indicating potential net proceeds below the gross amount.
Universe Pharmaceuticals has successfully completed its self-underwritten public offering on July 15, 2024, raising $25 million before expenses. The offering consisted of 20 million ordinary shares priced at $1.25 per share, with a par value of $0.01875 per share.The company, headquartered in Jiangxi, China, executed this capital raising initiative through a self-managed offering process, demonstrating direct market engagement. The funds were raised before deducting offering-related expenses, indicating potential net proceeds below the gross amount.
大自然藥業已於2024年7月15日成功完成了自行承銷的公開發行,籌集資金2500萬,尚未扣除費用。此次發行包括2000萬普通股,定價爲每股1.25美元,每股面值爲0.01875美元。該公司總部位於中國江西,通過自我管理的發行過程執行了這一融資舉措,展示了與市場的直接互動。這些資金在扣除與發行相關的費用之前籌集,表明潛在的淨收益可能低於總金額。
大自然藥業已於2024年7月15日成功完成了自行承銷的公開發行,籌集資金2500萬,尚未扣除費用。此次發行包括2000萬普通股,定價爲每股1.25美元,每股面值爲0.01875美元。該公司總部位於中國江西,通過自我管理的發行過程執行了這一融資舉措,展示了與市場的直接互動。這些資金在扣除與發行相關的費用之前籌集,表明潛在的淨收益可能低於總金額。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息